No Data
PacBio Announces Shipment of Vega Systems to Berry Genomics
Express News | PacBio Ships First Vega Systems To Berry Genomics For Clinical Assay Development In Asian Markets, With Plans For NMPA Regulatory Approval And Over 50 Additional Units Committed
Berry Genomics (000710.SZ): Plans to invest in the Fuzhou Xintou Zhi Kairui Kang Venture Capital Fund.
On December 30, Gelonghui reports that Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary Fujian Berry Health and Technology Co., Ltd. (referred to as "Berry Health and Technology") has signed the "Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership Agreement (Limited Partnership)" with Shanghai Zhikai Asset Management Co., Ltd., Fuzhou Xintou Venture Capital Co., Ltd., Shanghai Runda Medical Technology Co., Ltd., and Shanghai Fukai Ruikang Enterprise Management Consulting Partnership (Limited Partnership). Together, they will invest to establish the Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership (Limited Partnership), with a fundraising target scale of.
Retail Investors Invested in Berry Genomics Co.,Ltd (SZSE:000710) up 12% Last Week, Insiders Too Were Rewarded
Berry Genomics (000710.SZ): Currently, there are no genetic drugs for liver diseases, nor are there any research and development of tumor genetic vaccines.
On December 3, BioMap (000710.SZ) stated on the investor interaction platform that the company currently does not have liver disease genetic drug products, nor does it have research and development of tumor genetic vaccines. The company is dedicated to fully converting gene sequencing technology into clinical applications, focusing on areas such as reproductive health, genetic disease testing, tumor detection, and technology services. The company currently provides sequencing services for some innovative drug companies.
Berry Genomics (000710.SZ): The controlling shareholder Gao Yang has cumulatively passively reduced their shareholding by 0.9997% of the company's shares.
On October 31, GeLongHui announced that berry genomics (000710.SZ) recently received a notification letter from its controlling shareholder, Mr. Gao Yang, regarding the expiration of the shareholding reduction plan: During the current passive shareholding reduction plan, Mr. Gao Yang has cumulatively passively reduced 3,534,149 shares of the company's stock, accounting for approximately 0.9997% of the total share capital of the company.
We Think Berry GenomicsLtd (SZSE:000710) Has A Fair Chunk Of Debt
No Data
